Venture Global’s IPO stumble shows the limits of gassing up a valuation
More generally, markets have a way of recalibrating, and Venture Global’s IPO offers a nuanced lesson. It’s a reminder that valuations aren’t fixed by management or banker decree, but rather hammered out in the back-and-forth with investors.
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...
Even so the deal solidifies Venture Global’s place in the public markets with an impressive $50 billion market cap. And it ...
HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
Rexpro Enterprises IPO shows a grey market premium of ₹10, indicating a potential listing price of ₹155. The IPO was ...
The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...
Steel products maker Colform Group Bhd’s initial public offering (IPO) of 30 million shares has been oversubscribed by 41.82 ...
Czech steam-turbine manufacturer Doosan Skoda Power AS launched an initial public offering, touting an outlook for high ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback